Ariad Advances Drug for Resistant Leukemia Patients with MolecularMD's Companion Test
March 30, 2011
Ariad Advances Drug for Resistant Leukemia Patients with MolecularMD's Companion Test
"The MolecularMD companion diagnostic test is being developed to identify CML and Ph+ ALL patients who have the T315I mutation," Ariad said in a statement, adding that a companion diagnostic test "is not necessary to support the broader potential use of ponatinib," since many other mutations contribute to patients' resistance to BCR-ABL inhibitors.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA Approves Ariad's Iclusig for Molecularly Defined, TKI-Resistant Leukemias
December 19, 2012 / Pharmacogenomics Reporter - MolecularMD Pulls PMA After FDA Says Companion Dx Not Needed to Establish Ponatinib Efficacy, Safety
September 19, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: EC Approves Kalydeco; Cabozantinib in PGx-Targeted NSCLC; Ponatinib, CDx FDA Filing
August 1, 2012 / Pharmacogenomics Reporter - Medco Taps MolecularMD to Provide BCR-ABL Testing for TKI Inhibitors in CML Patients
June 8, 2011 / Pharmacogenomics Reporter - CMS Issues Pricing for MDx Codes; Labs, Test Developers Still Critical of Rates and Methodology
May 20, 2013 / Pharmacogenomics Reporter